You are here: Industry Insights > Diabetes

News List

FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment pharmaceutical-technology
May 06, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Med7 LLC, announce the completion of a safety and efficacy study using Hempzorb81TM Full Spectrum Hemp Oil in patients with Type II Diabetes prnewswire
April 30, 2021
Med7, LLC and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb® technology, now trademarked as Hempzorb81TM. "
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes americanpharmaceuticalreview
April 14, 2021
vTv Therapeutics Inc. a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Welldoc and Dexcom Expand Strategic Partnership to Integrate Platforms and Offer Integrated Type 2 Diabetes Management Solution americanpharmaceuticalreview
April 07, 2021
Welldoc announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes.
FDA refuses Novo Nordisk’s once-weekly semaglutide pharmatimes
March 25, 2021
Novo Nordisk has received a refusal to file letter from the US Food and Drug Administration (FDA) for a label expansion application for semaglutide.
Frontline charities sign open letter backing COVID-19 vaccination drive pharmatimes
March 17, 2021
A partnership of frontline health charities has signed an open letter encouraging people with underlying conditions to book in for a COVID-19 vaccine.
Lilly, Biolojic to develop antibody therapies for diabetes treatment pharmaceutical-business-review
March 15, 2021
Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment.
ViaCyte, Gore to Develop Technologies that Enhance Delivery of Therapies for Diabetes americanpharmaceuticalreview
March 05, 2021
ViaCyte and W. L. Gore & Associates announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte's portfolio of ...
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn pharmaceutical-technology
March 02, 2021
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 37 38 Next page